PL2531027T3 - Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę - Google Patents

Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę

Info

Publication number: PL2531027T3
Authority: PL; Poland
Prior art keywords: dolutegravir; abacavir; lamivudine; therapeutic combination; therapeutic
Prior art date: 2010-01-27

Application number

PL11737484T

Other languages

English (en)

Inventor

Mark Richard Underwood

Original Assignee

Viiv Healthcare Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-01-27

Filing date

2011-01-24

Publication date

2016-01-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44319704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2531027(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-01-24 Application filed by Viiv Healthcare Co filed Critical Viiv Healthcare Co

2016-01-29 Publication of PL2531027T3 publication Critical patent/PL2531027T3/pl

Links

UGWQMIXVUBLMAH-IVVFTGHFSA-N [(1s,4r)-4-[2-amino-6-(cyclopropylamino)purin-9-yl]cyclopent-2-en-1-yl]methanol;4-amino-1-[(2r,5s)-2-(hydroxymethyl)-1,3-oxathiolan-5-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1.C=12N=CN([C@H]3C=C[C@@H](CO)C3)C2=NC(N)=NC=1NC1CC1 UGWQMIXVUBLMAH-IVVFTGHFSA-N 0.000 title 1
RHWKPHLQXYSBKR-BMIGLBTASA-N dolutegravir Chemical compound C([C@@H]1OCC[C@H](N1C(=O)C1=C(O)C2=O)C)N1C=C2C(=O)NCC1=CC=C(F)C=C1F RHWKPHLQXYSBKR-BMIGLBTASA-N 0.000 title 1
229960002542 dolutegravir Drugs 0.000 title 1
230000001225 therapeutic effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Virology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Dermatology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Physiology (AREA)
Nutrition Science (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Molecular Biology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

PL11737484T 2010-01-27 2011-01-24 Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę PL2531027T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US29858910P	2010-01-27	2010-01-27
EP11737484.3A EP2531027B1 (en)	2010-01-27	2011-01-24	Therapeutic combination comprising dolutegravir, abacavir and lamivudine
PCT/US2011/022219 WO2011094150A1 (en)	2010-01-27	2011-01-24	Antiviral therapy

Publications (1)

Publication Number	Publication Date
PL2531027T3 true PL2531027T3 (pl)	2016-01-29

Family

ID=44319704

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL19151897.6T PL3494972T3 (pl)	2010-01-27	2011-01-24	Skojarzenie dolutegrawiru i lamiwudyny do leczenia zakażenia wirusem hiv
PL16187411T PL3127542T3 (pl)	2010-01-27	2011-01-24	Terapia przeciwwirusowa
PL11737484T PL2531027T3 (pl)	2010-01-27	2011-01-24	Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę
PL15164931T PL2932970T3 (pl)	2010-01-27	2011-01-24	Terapia antywirusowa

Family Applications Before (2)

Application Number	Title	Priority Date	Filing Date
PL19151897.6T PL3494972T3 (pl)	2010-01-27	2011-01-24	Skojarzenie dolutegrawiru i lamiwudyny do leczenia zakażenia wirusem hiv
PL16187411T PL3127542T3 (pl)	2010-01-27	2011-01-24	Terapia przeciwwirusowa

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL15164931T PL2932970T3 (pl)	2010-01-27	2011-01-24	Terapia antywirusowa

Country Status (45)

Country	Link
US (13)	US20120295898A1 (pl)
EP (6)	EP3127542B1 (pl)
JP (9)	JP2013518107A (pl)
KR (4)	KR101830715B1 (pl)
CN (2)	CN102791129B (pl)
AP (1)	AP3551A (pl)
AU (1)	AU2011209788C1 (pl)
BR (1)	BR112012018670A2 (pl)
CA (4)	CA2967453C (pl)
CL (1)	CL2012002080A1 (pl)
CO (1)	CO6602152A2 (pl)
CR (1)	CR20120423A (pl)
CY (6)	CY1116509T1 (pl)
DK (4)	DK3494972T3 (pl)
DO (2)	DOP2012000205A (pl)
EA (4)	EA037601B1 (pl)
EC (1)	ECSP12012106A (pl)
ES (4)	ES2543066T3 (pl)
FI (2)	FI3494972T3 (pl)
FR (2)	FR18C1043I2 (pl)
HK (1)	HK1250335A1 (pl)
HR (4)	HRP20240168T1 (pl)
HU (6)	HUE065569T2 (pl)
IL (5)	IL221007A (pl)
LT (5)	LT3494972T (pl)
LU (1)	LUC00090I2 (pl)
MA (1)	MA34002B1 (pl)
ME (2)	ME03058B (pl)
MX (4)	MX367938B (pl)
MY (3)	MY188334A (pl)
NO (2)	NO2932970T3 (pl)
NZ (4)	NZ627827A (pl)
PE (2)	PE20121524A1 (pl)
PH (3)	PH12012501537A1 (pl)
PL (4)	PL3494972T3 (pl)
PT (4)	PT2932970T (pl)
RS (4)	RS57728B1 (pl)
SG (3)	SG10201707183TA (pl)
SI (4)	SI2932970T1 (pl)
SM (4)	SMT201800290T1 (pl)
TN (1)	TN2012000376A1 (pl)
TR (1)	TR201807704T4 (pl)
UA (1)	UA105556C2 (pl)
WO (1)	WO2011094150A1 (pl)
ZA (1)	ZA201205586B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ627827A (en)	2010-01-27	2016-02-26	Viiv Healthcare Co	Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
BR112015006558A2 (pt)	2012-10-23	2017-07-04	Cipla Ltd	composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus
DK3067358T3 (da)	2012-12-21	2019-11-04	Gilead Sciences Inc	Polycykliske carbamoylpyridon-forbindelser og deres farmaceutiske anvendelse
EP2767272A1 (en) *	2013-02-18	2014-08-20	Ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
EP2956123A1 (en) *	2013-02-18	2015-12-23	ratiopharm GmbH	Solid pharmaceutical dosage form of dolutegravir
NO2865735T3 (pl)	2013-07-12	2018-07-21
PL3019503T3 (pl)	2013-07-12	2018-01-31	Gilead Sciences Inc	Policykliczne związki karbamoilopirydonowe i ich zastosowanie do leczenia infekcji hiv
EP3049081B1 (en)	2013-09-27	2019-11-27	Merck Sharp & Dohme Corp.	Substituted quinolizine derivatives useful as hiv integrase inhibitors
IN2014MU00916A (pl)	2014-03-20	2015-09-25	Cipla Ltd
US10300074B2 (en)	2014-06-04	2019-05-28	Sanford Burnham Prebys Medical Discovery Institute	Use of inhibitor of apoptosis protein (IAP) antagonists in HIV therapy
TWI744723B (zh)	2014-06-20	2021-11-01	美商基利科學股份有限公司	多環型胺甲醯基吡啶酮化合物之合成
NO2717902T3 (pl)	2014-06-20	2018-06-23
TW201613936A (en)	2014-06-20	2016-04-16	Gilead Sciences Inc	Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
WO2016016279A1 (en)	2014-07-29	2016-02-04	Lek Pharmaceuticals D.D.	Novel hydrates of dolutegravir sodium
TWI695003B (zh)	2014-12-23	2020-06-01	美商基利科學股份有限公司	多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3277691B1 (en)	2015-04-02	2019-01-30	Gilead Sciences, Inc.	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2017029225A1 (en) *	2015-08-14	2017-02-23	Sandoz Ag	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2017205585A1 (en) *	2016-05-27	2017-11-30	Viiv Healthcare Company	Combinations and uses treatments thereof
WO2018028841A1 (en) *	2016-08-12	2018-02-15	Sandoz Ag	Solid pharmaceutical composition of abacavir, lamivudine, and efavirenz
WO2018042332A1 (en) *	2016-08-31	2018-03-08	Glaxosmithkline Intellectual Property (No.2) Limited	Combinations and uses and treatments thereof
US20200138845A1 (en) *	2017-07-18	2020-05-07	Viiv Healthcare Company	Combination Drug Therapy
AU2018304591A1 (en)	2017-07-21	2020-03-05	Janssen Sciences Ireland Unlimited Company	Regimens for treating hiv infections and aids
JP2020528413A (ja) *	2017-07-21	2020-09-24	ヴィーブヘルスケアカンパニー	Ｈｉｖ感染症及びａｉｄｓを治療するためのレジメン
EP3694522B1 (en) *	2017-10-13	2025-11-26	VIIV Healthcare Company	Bi-layer pharmaceutical tablet formulation
WO2020197991A1 (en)	2019-03-22	2020-10-01	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
CN114901363A (zh) *	2020-01-09	2022-08-12	华盛顿大学	长效治疗剂组合物及其方法
IL295677A (en)	2020-02-24	2022-10-01	Gilead Sciences Inc	Tetracyclic compounds for treating hiv infection
US12421235B2 (en)	2020-09-30	2025-09-23	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
PT4196479T (pt)	2021-01-19	2024-01-03	Gilead Sciences Inc	Compostos de piridotriazinas substituídos e suas utilizações
CN114230579A (zh) *	2021-11-12	2022-03-25	南京艾迪医药科技有限公司	多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
AU2023225805A1 (en) *	2022-02-28	2024-10-17	Jericho Sciences, Llc	Methods for viral infections
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5047407A (en)	1989-02-08	1991-09-10	Iaf Biochem International, Inc.	2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties
US7119202B1 (en)	1989-02-08	2006-10-10	Glaxo Wellcome Inc.	Substituted-1,3-oxathiolanes and substituted-1,3-dioxolanes with antiviral properties
GB8815265D0 (en)	1988-06-27	1988-08-03	Wellcome Found	Therapeutic nucleosides
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
ZA923640B (en)	1991-05-21	1993-02-24	Iaf Biochem Int	Processes for the diastereoselective synthesis of nucleosides
GB9111902D0 (en)	1991-06-03	1991-07-24	Glaxo Group Ltd	Chemical compounds
GB9204015D0 (en)	1992-02-25	1992-04-08	Wellcome Found	Therapeutic nucleosides
US5663169A (en)	1992-08-07	1997-09-02	Merck & Co., Inc.	Benzoxazinones as inhibitors of HIV reverse transcriptase
IL106507A (en)	1992-08-07	1997-11-20	Merck & Co Inc	Pharmaceutical compositions containing benzoxazinones and some novel compounds of this type
GB9402161D0 (en)	1994-02-04	1994-03-30	Wellcome Found	Chloropyrimidine intermediates
IL113432A (en)	1994-04-23	2000-11-21	Glaxo Group Ltd	Process for the diastereoselective synthesis of nucleoside analogues
UA49803C2 (uk)	1994-06-03	2002-10-15	Дж.Д. Сьорль Енд Ко	Спосіб лікування ретровірусних інфекцій
MY115461A (en)	1995-03-30	2003-06-30	Wellcome Found	Synergistic combinations of zidovudine, 1592u89 and 3tc
US5914332A (en)	1995-12-13	1999-06-22	Abbott Laboratories	Retroviral protease inhibiting compounds
US5849911A (en)	1996-04-22	1998-12-15	Novartis Finance Corporation	Antivirally active heterocyclic azahexane derivatives
EA001517B1 (ru) *	1996-06-25	2001-04-23	Глаксо Груп Лимитед	Комбинации, содержащие vx478, зидовудин и 3tc, для применения при лечении вич
US5922695A (en)	1996-07-26	1999-07-13	Gilead Sciences, Inc.	Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5965729A (en)	1997-02-05	1999-10-12	Merck & Co., Inc.	Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
GB9709945D0 (en)	1997-05-17	1997-07-09	Glaxo Group Ltd	A novel salt
US5935946A (en)	1997-07-25	1999-08-10	Gilead Sciences, Inc.	Nucleotide analog composition and synthesis method
GB9717928D0 (en)	1997-08-22	1997-10-29	Glaxo Group Ltd	Process for the enatioselective hydrolysis of n-derivatised lactams
GB9721780D0 (en)	1997-10-14	1997-12-10	Glaxo Group Ltd	Process for the synthesis of chloropurine intermediates
US6436989B1 (en)	1997-12-24	2002-08-20	Vertex Pharmaceuticals, Incorporated	Prodrugs of aspartyl protease inhibitors
US6087383A (en)	1998-01-20	2000-07-11	Bristol-Myers Squibb Company	Bisulfate salt of HIV protease inhibitor
GB9805898D0 (en)	1998-03-20	1998-05-13	Glaxo Group Ltd	Process for the sythesis of hiv protease inhibitors
AU3366899A (en)	1998-03-27	1999-10-18	Regents Of The University Of California, The	Novel hiv integrase inhibitors and hiv therapy based on drug combinations including integrase inhibitors
UA72207C2 (uk)	1998-04-07	2005-02-15	Брістол- Майєрс Сквібб Фарма Компані	Фармацевтична композиція ефавіренцу з добавкою дезінтегруючих агентів у вигляді швидкорозчинних капсул або таблеток та спосіб її виготовлення
GB9809213D0 (en) *	1998-04-29	1998-07-01	Glaxo Group Ltd	Pharmaceutical compositions
GB9815567D0 (en)	1998-07-18	1998-09-16	Glaxo Group Ltd	Antiviral compound
EP2329796B1 (en)	2000-01-31	2021-09-01	Cook Biotech Incorporated	Stent valve
AU2002242926B2 (en)	2001-04-10	2007-10-11	Pfizer Inc.	Pyrazole derivatives for treating HIV
US7638522B2 (en) *	2001-08-13	2009-12-29	Janssen Pharmaceutica N.V.	Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
MY169670A (en)	2003-09-03	2019-05-08	Tibotec Pharm Ltd	Combinations of a pyrimidine containing nnrti with rt inhibitors
JO3429B1 (ar)	2001-08-13	2019-10-20	Janssen Pharmaceutica Nv	مشتقات برميدينات مثبطة فيروس الايدز
AR040242A1 (es) *	2002-06-04	2005-03-23	Glaxo Group Ltd	Composiciones farmaceuticas
BR0311141A (pt) *	2002-06-27	2005-06-07	Medivir Ab	Interação sinergìstica de abacavir e alovudine
US20040224917A1 (en) *	2003-01-14	2004-11-11	Gilead Sciences, Inc.	Compositions and methods for combination antiviral therapy
TW200510425A (en)	2003-08-13	2005-03-16	Japan Tobacco Inc	Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4859676B2 (ja) *	2004-02-11	2012-01-25	スミスクラインビーチャムコーポレーション	Ｈｉｖインテグラーゼ阻害剤
JP4285353B2 (ja)	2004-03-05	2009-06-24	清水建設株式会社	化学物質放散度評価方法
DK1742642T3 (da) *	2004-04-14	2009-02-16	Gilead Sciences Inc	Phosphonatanaloge af HIV-integraseinhibitorforbindelser
WO2005112930A1 (en) *	2004-05-21	2005-12-01	Japan Tobacco Inc.	Combinations comprising a 4-isoquinolone derivative and anti-hiv agents
US7176196B2 (en)	2004-05-28	2007-02-13	Bristol-Myers Squibb Company	Bicyclic heterocycles as HIV integrase inhibitors
KR20070043043A (ko)	2004-08-23	2007-04-24	테바 파마슈티컬 인더스트리즈 리미티드	고체 및 결정 이반드로네이트 나트륨 및 이들의 제조 방법
CA2577288C (en)	2004-09-02	2010-11-30	Janssen Pharmaceutica N.V.	Hydrochloride of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
EP1799696B1 (en)	2004-09-17	2008-11-12	IDENIX Pharmaceuticals, Inc.	Phosphoindoles as hiv inhibitors
US7250421B2 (en)	2005-01-31	2007-07-31	University Of Georgia Research Foundation, Inc.	Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
WO2006096444A2 (en)	2005-03-04	2006-09-14	Smithkline Beecham Corporation	Chemical compounds
CN101212903B (zh) *	2005-04-28	2013-07-24	史密丝克莱恩比彻姆公司	具有hiv整合酶抑制活性的多环氨基甲酰基吡啶酮衍生物
JP4295353B2 (ja)	2005-04-28	2009-07-15	スミスクラインビーチャムコーポレーション	Ｈｉｖインテグラーゼ阻害活性を有する多環性カルバモイルピリドン誘導体
WO2006129134A1 (en)	2005-06-01	2006-12-07	Bioalliance Pharma	Synergic combinations comprising a styrylquinoline compound and other hiv infection therapeutic agents
SG170796A1 (en)	2005-12-30	2011-05-30	Gilead Sciences Inc Us	Methods for improving the pharmacokinetics of hiv integrase inhibitors
UA108605C2 (uk) *	2005-12-30	2015-05-25		Спосіб покращення фармакокінетики інгібіторів інтегрази віл
SI1981506T1 (sl) *	2006-01-20	2013-08-30	Janssen R&D Ireland	Dolgoročno zdravljenje infekcije HIV s TCM278
US20080039428A1 (en)	2006-06-29	2008-02-14	Panacos Pharmaceuticals, Inc.	Antiretroviral combination therapy
US20090306112A1 (en)	2006-07-21	2009-12-10	Gilead Sciences, Inc.	Antiviral protease inhibitors
ES2488922T3 (es)	2006-09-29	2014-09-01	Idenix Pharmaceuticals, Inc.	Fosfoindoles enantiómeramente puros como inhibidores del HIV
ES2602784T3 (es)	2007-02-23	2017-02-22	Gilead Sciences, Inc.	Moduladores de las propiedades farmacocinéticas de los agentes terapéuticos
WO2008103899A1 (en)	2007-02-23	2008-08-28	Auspex Pharmaceuticals, Inc.	Preparation and utility of non-nucleoside reverse transcriptase inhibitors
CA2692460A1 (en)	2007-06-29	2009-01-08	Korea Research Institute Of Chemical Technology	Hiv reverse transcriptase inhibitors
KR20100041798A (ko)	2007-06-29	2010-04-22	한국화학연구원	신규 ｈｉｖ 역전사효소 억제제
CN101796040A (zh)	2007-07-06	2010-08-04	吉里德科学公司	治疗剂的药代动力学特性调节剂
AU2008274185B2 (en)	2007-07-12	2014-07-03	Janssen Sciences Ireland Uc	Crystalline form of (E) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
WO2009058923A1 (en)	2007-10-31	2009-05-07	Smithkline Beecham Corporation	Ccr5 antagonists as therapeutic agents
JP2011502998A (ja)	2007-11-01	2011-01-27	ザユーエイビーリサーチファウンデイション	ウイルス感染の治療および予防
US8108055B2 (en)	2007-12-28	2012-01-31	Larry Wong	Method, system and apparatus for controlling an electrical device
WO2009082819A1 (en) *	2008-01-03	2009-07-09	Virochem Pharma Inc.	Novel lupane derivatives
CN101977924A (zh)	2008-01-03	2011-02-16	Viro化学制药公司	新的c-21-酮基羽扇烷衍生物、其制备方法和应用
JP5629585B2 (ja)	2008-01-04	2014-11-19	ギリアードサイエンシーズ，インコーポレイテッド	シトクロムｐ４５０のインヒビター
EP2257567A1 (en)	2008-02-14	2010-12-08	Virochem Pharma Inc.	Novel 17 beta lupane derivatives
WO2009148600A2 (en) *	2008-06-06	2009-12-10	Concert Pharmaceuticals, Inc.	Deuterated lysine-based compounds
WO2010011812A1 (en) *	2008-07-25	2010-01-28	Smithkline Beecham Corporation	Chemical compounds
EP3210603A1 (en)	2008-12-11	2017-08-30	Shionogi & Co., Ltd	Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
WO2010068262A1 (en)	2008-12-11	2010-06-17	Glaxosmithkline Llc	Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
NZ627827A (en)	2010-01-27	2016-02-26	Viiv Healthcare Co	Antiviral combinations involving (3s, 11ar)-n-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide
GB201006038D0 (en)	2010-04-12	2010-05-26	Unilever Plc	Improvements relating to antiviral compositions
CN103402516B (zh)	2010-06-17	2018-01-30	富津世生物技术有限公司	用作抗病毒药物的化合物、组合物及使用方法
BR112013025368A8 (pt)	2011-04-01	2018-06-12	The Medicines Co	Medicamento, método para preparar um medicamento útil para reduzir danos por derrame em um sujeito com derrame, método para preparar um medicamento útil para reduzir a pressão sanguínea e reduzir danos por derrame em um sujeito com derrame

2011
- 2011-01-24 NZ NZ627827A patent/NZ627827A/en unknown
- 2011-01-24 HU HUE19151897A patent/HUE065569T2/hu unknown
- 2011-01-24 PL PL19151897.6T patent/PL3494972T3/pl unknown
- 2011-01-24 JP JP2012551213A patent/JP2013518107A/ja active Pending
- 2011-01-24 HR HRP20240168TT patent/HRP20240168T1/hr unknown
- 2011-01-24 RS RS20181178A patent/RS57728B1/sr unknown
- 2011-01-24 ME MEP-2018-131A patent/ME03058B/me unknown
- 2011-01-24 MX MX2014014687A patent/MX367938B/es unknown
- 2011-01-24 PL PL16187411T patent/PL3127542T3/pl unknown
- 2011-01-24 DK DK19151897.6T patent/DK3494972T3/da active
- 2011-01-24 RS RS20150462A patent/RS54123B1/sr unknown
- 2011-01-24 MX MX2012008774A patent/MX2012008774A/es active IP Right Grant
- 2011-01-24 AU AU2011209788A patent/AU2011209788C1/en active Active
- 2011-01-24 EA EA201892277A patent/EA037601B1/ru active Protection Beyond IP Right Term
- 2011-01-24 SG SG10201707183TA patent/SG10201707183TA/en unknown
- 2011-01-24 NO NO15164931A patent/NO2932970T3/no unknown
- 2011-01-24 PL PL11737484T patent/PL2531027T3/pl unknown
- 2011-01-24 HU HUE15164931A patent/HUE037812T2/hu unknown
- 2011-01-24 MX MX2014014688A patent/MX367937B/es unknown
- 2011-01-24 PT PT151649316T patent/PT2932970T/pt unknown
- 2011-01-24 EP EP16187411.0A patent/EP3127542B1/en active Active
- 2011-01-24 CA CA2967453A patent/CA2967453C/en active Active
- 2011-01-24 SM SM20180290T patent/SMT201800290T1/it unknown
- 2011-01-24 LT LTEP19151897.6T patent/LT3494972T/lt unknown
- 2011-01-24 PT PT191518976T patent/PT3494972T/pt unknown
- 2011-01-24 LT LTEP16187411.0T patent/LT3127542T/lt unknown
- 2011-01-24 HU HUE11737484A patent/HUE026849T2/en unknown
- 2011-01-24 ES ES11737484.3T patent/ES2543066T3/es active Active
- 2011-01-24 EA EA201690872A patent/EA032868B1/ru active Protection Beyond IP Right Term
- 2011-01-24 LT LTEP15164931.6T patent/LT2932970T/lt unknown
- 2011-01-24 US US13/575,380 patent/US20120295898A1/en not_active Abandoned
- 2011-01-24 HR HRP20150770TT patent/HRP20150770T1/hr unknown
- 2011-01-24 SI SI201131492T patent/SI2932970T1/en unknown
- 2011-01-24 BR BR112012018670-1A patent/BR112012018670A2/pt not_active Application Discontinuation
- 2011-01-24 HU HUE16187411A patent/HUE040554T2/hu unknown
- 2011-01-24 KR KR1020127022254A patent/KR101830715B1/ko active Active
- 2011-01-24 CA CA2787691A patent/CA2787691C/en active Active
- 2011-01-24 MY MYPI2012003346A patent/MY188334A/en unknown
- 2011-01-24 NZ NZ601319A patent/NZ601319A/en unknown
- 2011-01-24 RS RS20240189A patent/RS65183B1/sr unknown
- 2011-01-24 PL PL15164931T patent/PL2932970T3/pl unknown
- 2011-01-24 KR KR1020177017713A patent/KR20170078868A/ko not_active Ceased
- 2011-01-24 PT PT16187411T patent/PT3127542T/pt unknown
- 2011-01-24 SM SM20240063T patent/SMT202400063T1/it unknown
- 2011-01-24 CA CA3060290A patent/CA3060290C/en active Active
- 2011-01-24 SG SG10201509476RA patent/SG10201509476RA/en unknown
- 2011-01-24 PE PE2012001082A patent/PE20121524A1/es active IP Right Grant
- 2011-01-24 FI FIEP19151897.6T patent/FI3494972T3/fi active
- 2011-01-24 PE PE2016000261A patent/PE20160180A1/es unknown
- 2011-01-24 SI SI201132101T patent/SI3494972T1/sl unknown
- 2011-01-24 WO PCT/US2011/022219 patent/WO2011094150A1/en not_active Ceased
- 2011-01-24 EP EP23214771.0A patent/EP4316599A3/en active Pending
- 2011-01-24 NZ NZ627824A patent/NZ627824A/en unknown
- 2011-01-24 DK DK16187411.0T patent/DK3127542T3/en active
- 2011-01-24 TR TR2018/07704T patent/TR201807704T4/tr unknown
- 2011-01-24 MY MYPI2021001818A patent/MY207233A/en unknown
- 2011-01-24 EA EA201290583A patent/EA025176B1/ru active Protection Beyond IP Right Term
- 2011-01-24 EA EA202190473A patent/EA202190473A3/ru unknown
- 2011-01-24 ES ES16187411.0T patent/ES2688925T3/es active Active
- 2011-01-24 EP EP15164931.6A patent/EP2932970B1/en not_active Revoked
- 2011-01-24 SM SM20180594T patent/SMT201800594T1/it unknown
- 2011-01-24 ES ES19151897T patent/ES2969969T3/es active Active
- 2011-01-24 MY MYPI2019000564A patent/MY202778A/en unknown
- 2011-01-24 CA CA3003988A patent/CA3003988C/en active Active
- 2011-01-24 ME MEP-2015-106A patent/ME02182B/me unknown
- 2011-01-24 EP EP18161536.0A patent/EP3351249A1/en not_active Withdrawn
- 2011-01-24 MX MX2014014689A patent/MX356891B/es unknown
- 2011-01-24 CN CN201180015114.8A patent/CN102791129B/zh active Active
- 2011-01-24 MA MA35145A patent/MA34002B1/fr unknown
- 2011-01-24 ES ES15164931.6T patent/ES2670811T3/es active Active
- 2011-01-24 DK DK11737484.3T patent/DK2531027T3/en active
- 2011-01-24 RS RS20180667A patent/RS57323B1/sr unknown
- 2011-01-24 AP AP2012006445A patent/AP3551A/xx active
- 2011-01-24 KR KR1020187018909A patent/KR101964923B1/ko active Active
- 2011-01-24 EP EP19151897.6A patent/EP3494972B1/en active Active
- 2011-01-24 NZ NZ627826A patent/NZ627826A/en unknown
- 2011-01-24 PH PH1/2012/501537A patent/PH12012501537A1/en unknown
- 2011-01-24 PT PT117374843T patent/PT2531027E/pt unknown
- 2011-01-24 SI SI201130539T patent/SI2531027T1/sl unknown
- 2011-01-24 DK DK15164931.6T patent/DK2932970T3/en active
- 2011-01-24 CN CN201510619148.8A patent/CN105311033B/zh active Active
- 2011-01-24 SG SG2012053492A patent/SG182614A1/en unknown
- 2011-01-24 UA UAA201209253A patent/UA105556C2/uk unknown
- 2011-01-24 EP EP11737484.3A patent/EP2531027B1/en not_active Revoked
- 2011-01-24 KR KR1020167025050A patent/KR101883750B1/ko active Active
- 2011-01-24 SI SI201131593T patent/SI3127542T1/sl unknown
2012
- 2012-07-18 IL IL221007A patent/IL221007A/en active IP Right Grant
- 2012-07-18 DO DO2012000205A patent/DOP2012000205A/es unknown
- 2012-07-24 TN TNP2012000376A patent/TN2012000376A1/en unknown
- 2012-07-24 ZA ZA2012/05586A patent/ZA201205586B/en unknown
- 2012-07-26 CL CL2012002080A patent/CL2012002080A1/es unknown
- 2012-07-26 CO CO12125933A patent/CO6602152A2/es active IP Right Grant
- 2012-08-13 CR CR20120423A patent/CR20120423A/es unknown
- 2012-08-14 EC ECSP12012106 patent/ECSP12012106A/es unknown
2013
- 2013-06-06 HK HK18109751.0A patent/HK1250335A1/en unknown
2015
- 2015-05-13 US US14/710,952 patent/US20150238496A1/en not_active Abandoned
- 2015-07-17 CY CY20151100633T patent/CY1116509T1/el unknown
- 2015-07-24 SM SM201500177T patent/SMT201500177B/xx unknown
2016
- 2016-01-28 PH PH12016500195A patent/PH12016500195B1/en unknown
- 2016-01-29 JP JP2016015242A patent/JP2016145204A/ja active Pending
- 2016-03-18 US US15/073,728 patent/US20160199379A1/en not_active Abandoned
- 2016-04-18 IL IL245182A patent/IL245182B/en active IP Right Grant
- 2016-08-01 US US15/224,865 patent/US20160339033A1/en not_active Abandoned
- 2016-08-22 JP JP2016161610A patent/JP6268386B2/ja active Active
- 2016-12-01 US US15/366,566 patent/US20170119777A1/en not_active Abandoned
- 2016-12-01 US US15/366,442 patent/US10426780B2/en active Active
2017
- 2017-04-19 US US15/490,944 patent/US20170216284A1/en not_active Abandoned
- 2017-06-13 US US15/620,859 patent/US20170281636A1/en not_active Abandoned
- 2017-12-12 US US15/838,738 patent/US20180098992A1/en not_active Abandoned
2018
- 2018-01-31 IL IL257267A patent/IL257267B/en active IP Right Grant
- 2018-03-15 US US15/922,240 patent/US20180200254A1/en not_active Abandoned
- 2018-04-05 JP JP2018072861A patent/JP2018127473A/ja active Pending
- 2018-05-23 CY CY20181100548T patent/CY1120457T1/el unknown
- 2018-05-30 HR HRP20180855TT patent/HRP20180855T1/hr unknown
- 2018-09-26 HR HRP20181531TT patent/HRP20181531T1/hr unknown
- 2018-10-15 FR FR18C1043C patent/FR18C1043I2/fr active Active
- 2018-10-15 NO NO2018036C patent/NO2018036I1/no unknown
- 2018-10-16 CY CY2018029C patent/CY2018029I1/el unknown
- 2018-10-22 LT LTPA2018013C patent/LTC2932970I2/lt unknown
- 2018-10-23 CY CY181101087T patent/CY1121040T1/el unknown
- 2018-10-26 HU HUS1800042C patent/HUS1800042I1/hu unknown
- 2018-10-31 LU LU00090C patent/LUC00090I2/en unknown
- 2018-11-26 PH PH12018502489A patent/PH12018502489A1/en unknown
2019
- 2019-06-07 JP JP2019106635A patent/JP2019167371A/ja active Pending
- 2019-06-26 IL IL267658A patent/IL267658B/en active IP Right Grant
2020
- 2020-03-31 US US16/835,733 patent/US11234985B2/en active Active
2021
- 2021-02-26 JP JP2021030306A patent/JP7724619B2/ja active Active
- 2021-04-01 IL IL281959A patent/IL281959B/en unknown
- 2021-07-14 DO DO2021000147A patent/DOP2021000147A/es unknown
- 2021-09-08 US US17/468,794 patent/US20210401850A1/en not_active Abandoned
2022
- 2022-03-03 JP JP2022032464A patent/JP2022071126A/ja active Pending
2023
- 2023-04-04 JP JP2023060638A patent/JP2023085431A/ja active Pending
2024
- 2024-02-16 CY CY20241100135T patent/CY1126771T1/el unknown
- 2024-05-31 LT LTPA2024516C patent/LTC3494972I2/lt unknown
- 2024-05-31 FI FIC20240016C patent/FIC20240016I1/fi unknown
- 2024-06-03 HU HUS2400017C patent/HUS2400017I1/hu unknown
- 2024-06-04 CY CY2024017C patent/CY2024017I2/el unknown
- 2024-06-06 FR FR24C1024C patent/FR24C1024I2/fr active Active
- 2024-10-01 US US18/903,013 patent/US20250017939A1/en active Pending
2025
- 2025-06-02 JP JP2025091741A patent/JP2025131664A/ja active Pending

Also Published As

Publication number	Publication date
CA3003988C (en)	2020-01-07
EA037601B1 (ru)	2021-04-20
HUE037812T2 (hu)	2018-09-28
JP2017008087A (ja)	2017-01-12
LUC00090I2 (pl)	2019-01-08
MY202778A (en)	2024-05-21
CA2787691A1 (en)	2011-08-04
MX356891B (es)	2018-06-19
US20170119777A1 (en)	2017-05-04
IL257267A (en)	2018-03-29
CY1121040T1 (el)	2019-12-11
US20200230147A1 (en)	2020-07-23
KR101883750B1 (ko)	2018-07-31
EP3127542B1 (en)	2018-08-22
KR101830715B1 (ko)	2018-04-04
CY1126771T1 (el)	2025-05-09
DK3494972T3 (da)	2024-01-29
PL3127542T3 (pl)	2019-03-29
EP2531027A4 (en)	2013-07-03
MA34002B1 (fr)	2013-02-01
KR20160111536A (ko)	2016-09-26
FR24C1024I1 (fr)	2024-07-26
IL257267B (en)	2019-08-29
US20180098992A1 (en)	2018-04-12
EP2531027A1 (en)	2012-12-12
JP2019167371A (ja)	2019-10-03
CY2024017I1 (el)	2025-05-09
US20250017939A1 (en)	2025-01-16
LT3127542T (lt)	2018-11-26
US20120295898A1 (en)	2012-11-22
SMT202400063T1 (it)	2024-03-13
IL267658B (en)	2021-04-29
US11234985B2 (en)	2022-02-01
EA201690872A3 (ru)	2016-12-30
JP2023085431A (ja)	2023-06-20
FIC20240016I1 (fi)	2024-05-31
MY188334A (en)	2021-11-30
CY1120457T1 (el)	2019-07-10
LT3494972T (lt)	2024-03-12
KR20120128640A (ko)	2012-11-27
US20180200254A1 (en)	2018-07-19
US20170281636A1 (en)	2017-10-05
IL281959A (en)	2021-05-31
SMT201500177B (it)	2015-09-07
PT3127542T (pt)	2018-11-26
DK3127542T3 (en)	2018-11-12
US20160199379A1 (en)	2016-07-14
EA201892277A1 (ru)	2019-03-29
CA2967453C (en)	2018-07-17
US20170216284A1 (en)	2017-08-03
AU2011209788C1 (en)	2014-08-28
CN102791129B (zh)	2015-09-30
NZ627827A (en)	2016-02-26
NO2018036I1 (no)	2018-10-15
HK1250335A1 (en)	2018-12-14
KR20170078868A (ko)	2017-07-07
PT2531027E (pt)	2015-09-16
MX2012008774A (es)	2012-08-17
NZ601319A (en)	2014-08-29
DK2932970T3 (en)	2018-05-28
HUE065569T2 (hu)	2024-06-28
MX367938B (es)	2019-09-12
PH12016500195A1 (en)	2016-12-05
HRP20180855T1 (hr)	2018-06-29
KR20180078358A (ko)	2018-07-09
CA3060290C (en)	2022-07-12
HK1179522A1 (en)	2013-10-04
ES2670811T3 (es)	2018-06-01
FR24C1024I2 (fr)	2025-06-27
EP3351249A1 (en)	2018-07-25
JP2016145204A (ja)	2016-08-12
ECSP12012106A (es)	2013-05-31
CY2018029I2 (el)	2019-07-10
HRP20240168T1 (hr)	2024-04-26
IL221007A (en)	2016-06-30
RS57323B1 (sr)	2018-08-31
SG182614A1 (en)	2012-08-30
SMT201800290T1 (it)	2018-07-17
EP4316599A2 (en)	2024-02-07
NO2932970T3 (pl)	2018-08-18
CA2967453A1 (en)	2011-08-04
JP2013518107A (ja)	2013-05-20
ME02182B (me)	2015-10-20
HUS2400017I1 (hu)	2024-06-28
IL267658A (en)	2019-08-29
CA2787691C (en)	2018-07-17
US20210401850A1 (en)	2021-12-30
US20150238496A1 (en)	2015-08-27
NZ627824A (en)	2016-02-26
LTC2932970I2 (lt)	2022-04-25
PT3494972T (pt)	2024-02-12
JP2018127473A (ja)	2018-08-16
CA3003988A1 (en)	2011-08-04
DOP2021000147A (es)	2022-01-16
JP7724619B2 (ja)	2025-08-18
DK2531027T3 (en)	2015-07-20
PL3494972T3 (pl)	2024-05-27
KR101964923B1 (ko)	2019-04-02
HK1209629A1 (en)	2016-04-08
EP2932970A1 (en)	2015-10-21
AP2012006445A0 (en)	2012-08-31
CY2018029I1 (el)	2019-07-10
CA3060290A1 (en)	2011-08-04
CR20120423A (es)	2012-11-22
UA105556C2 (uk)	2014-05-26
JP2021091705A (ja)	2021-06-17
EP2932970B1 (en)	2018-03-21
EA201690872A2 (ru)	2016-08-31
FI3494972T3 (fi)	2024-03-01
ME03058B (me)	2019-01-20
CN102791129A (zh)	2012-11-21
EP2531027B1 (en)	2015-05-06
SG10201707183TA (en)	2017-10-30
ES2688925T3 (es)	2018-11-07
EA201290583A1 (ru)	2013-04-30
JP6268386B2 (ja)	2018-01-31
HUE040554T2 (hu)	2019-03-28
SG10201509476RA (en)	2015-12-30
PH12012501537A1 (en)	2018-02-07
IL245182B (en)	2018-04-30
FR18C1043I2 (fr)	2019-10-11
JP2022071126A (ja)	2022-05-13
US20160339033A1 (en)	2016-11-24
EA202190473A3 (ru)	2021-12-31
AP3551A (en)	2016-01-18
CY2024017I2 (el)	2025-05-09
CN105311033A (zh)	2016-02-10
HUE026849T2 (en)	2016-08-29
EP3494972B1 (en)	2023-12-13
HRP20181531T1 (hr)	2018-11-16
HUS1800042I1 (hu)	2018-11-28
SI3127542T1 (sl)	2018-11-30
LTC3494972I2 (pl)	2025-11-10
ES2543066T3 (es)	2015-08-14
DOP2012000205A (es)	2012-10-15
ES2969969T3 (es)	2024-05-23
TN2012000376A1 (en)	2014-01-30
RS57728B1 (sr)	2018-12-31
PL2932970T3 (pl)	2018-08-31
RS65183B1 (sr)	2024-03-29
PE20160180A1 (es)	2016-05-04
ZA201205586B (en)	2014-01-29
TR201807704T4 (tr)	2018-06-21
BR112012018670A2 (pt)	2018-02-06
CL2012002080A1 (es)	2012-11-30
US20170079982A1 (en)	2017-03-23
JP2025131664A (ja)	2025-09-09
PH12018502489A1 (en)	2020-06-15
HRP20150770T1 (hr)	2015-08-28
NZ627826A (en)	2016-01-29
LTPA2018013I1 (lt)	2018-11-12
AU2011209788B2 (en)	2014-02-06
LTPA2024516I1 (pl)	2024-06-25
AU2011209788A1 (en)	2012-08-16
IL245182A0 (en)	2016-06-30
CY1116509T1 (el)	2017-03-15
MY207233A (en)	2025-02-07
EP3127542A1 (en)	2017-02-08
IL281959B (en)	2021-12-01
SI2531027T1 (sl)	2015-08-31
EA025176B1 (ru)	2016-11-30
CO6602152A2 (es)	2013-01-18
WO2011094150A1 (en)	2011-08-04
PE20121524A1 (es)	2012-12-03
LT2932970T (lt)	2018-06-25
EA032868B1 (ru)	2019-07-31
US10426780B2 (en)	2019-10-01
CN105311033B (zh)	2019-05-07
FR18C1043I1 (pl)	2018-11-30
PT2932970T (pt)	2018-06-08
EP3494972A1 (en)	2019-06-12
EP4316599A3 (en)	2024-04-10
IL221007A0 (en)	2012-09-24
EA202190473A2 (ru)	2021-06-30
MX367937B (es)	2019-09-12
SI2932970T1 (en)	2018-07-31
PH12016500195B1 (en)	2021-08-04
SMT201800594T1 (it)	2019-01-11
RS54123B1 (sr)	2015-12-31
SI3494972T1 (sl)	2024-03-29

Publication	Publication Date	Title
PL2531027T3 (pl)	2016-01-29	Kombinacja terapeutyczna zawierająca dolutegrawir, abakawir i lamiwudynę
GB201012175D0 (en)	2010-09-01	Procedure and mechanisms
GB201010193D0 (en)	2010-07-21	Medicinal use
PT2536400E (pt)	2014-11-27	Medicamento contendo myramistin
GB201005394D0 (en)	2010-05-12	Therapy
GB0905485D0 (en)	2009-05-13	Antiviral therapy
GB0916997D0 (en)	2009-11-11	Combination therapy
GB201011138D0 (en)	2010-08-18	Vaporiser
GB0907973D0 (en)	2009-06-24	Combination therapy
GB0901487D0 (en)	2009-03-11	Asthma Therapy
EP2629766A4 (en)	2014-05-14	COMBINATION THERAPY
GB0922098D0 (en)	2010-02-03	Therapeutic use
GB0903319D0 (en)	2009-04-08	Therapy
GB0903321D0 (en)	2009-04-08	Therapy
GB0921244D0 (en)	2010-01-20	Therapy
GB0914820D0 (en)	2009-09-30	WATerian therapy
GB0903145D0 (en)	2009-04-08	Medicaments uses and methods
GB0908952D0 (en)	2009-07-01	Antiviral therapy
GB0904261D0 (en)	2009-04-22	New therapeutic use
GB0903318D0 (en)	2009-04-08	Medicament
GB0901902D0 (en)	2009-03-11	Medicament
AU332227S (en)	2010-08-17	Therapeutic pillow
GB0901155D0 (en)	2009-03-11	Vaporisers